Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cancer Cell International
Published in: Cancer Cell International 1/2020

Open Access 01-12-2020 | Colorectal Cancer | Primary research

RUNX2 interacts with BRG1 to target CD44 for promoting invasion and migration of colorectal cancer cells

Authors: Xiaodong Yan, Dali Han, Zhiqiang Chen, Chao Han, Wei Dong, Li Han, Lei Zou, Jianbo Zhang, Yan Liu, Jie Chai

Published in: Cancer Cell International | Issue 1/2020

Login to get access

Abstract

Background

Cancer stem cells (CSCs) play an important role in tumor invasion and metastasis. CD44 is the most commonly used marker of CSCs, with the potential to act as a determinant against the invasion and migration of CSCs and as the key factor in epithelial–mesenchymal transition (EMT)-like changes that occur in colorectal cancer (CRC). Runt-related transcription factor-2 (RUNX2) is a mesenchymal stem marker for cancer that is involved in stem cell biology and tumorigenesis. However, whether RUNX2 is involved in CSC and in inducing EMT-like changes in CRC remains uncertain, warranting further investigation.

Methods

We evaluated the role of RUNX2 in the invasion and migration of CRC cells as a promoter of CD44-induced stem cell- and EMT-like modifications. For this purpose, western blotting was employed to analyze the expression of differential proteins in CRC cells. We conducted sphere formation, wound healing, and transwell assays to investigate the biological functions of RUNX2 in CRC cells. Cellular immunofluorescence and coimmunoprecipitation (co-IP) assays were performed to study the relationship between RUNX2 and BRG1. Real-time quantitative PCR (RT-qPCR) and immunohistochemistry (IHC) were performed to analyze the expressions of RUNX2, BRG1, and CD44 in the CRC tissues.

Results

We found that RUNX2 could markedly induce the CRC cell sphere-forming ability and EMT. Interestingly, the RUNX2-mediated EMT in CRC cell may be associated with the activation of CD44. Furthermore, RUNX2 was found to interact with BRG1 to promote the recruitment of RUNX2 to the CD44 promoter.

Conclusions

Our cumulative findings suggest that RUNX2 and BRG1 can form a compact complex to regulate the transcription and expression of CD44, which has possible involvement in the invasion and migration of CRC cells.
Appendix
Available only for authorised users
Literature
1.
2.
Nandy SB, Lakshmanaswamy R. Cancer stem cells and metastasis. Prog Mol Biol Transl Sci. 2017;151:137–76.PubMedCrossRef
3.
4.
Jing F, et al. Colon cancer stem cell markers CD44 and CD133 in patients with colorectal cancer and synchronous hepatic metastases. Int J Oncol. 2015;46(4):1582–8.PubMedCrossRef
5.
6.
7.
Ibrahim HM, et al. Prognostic value of cyclin D1 and CD44 expression in gastric adenocarcinoma. J Gastrointest Cancer. 2019;50(3):370–9.PubMedCrossRef
8.
Chaffer CL, et al. EMT, cell plasticity and metastasis. Cancer Metastasis Rev. 2016;35(4):645–54.PubMedCrossRef
9.
Gloushankova NA, Zhitnyak IY, Rubtsova SN. Role of epithelial-mesenchymal transition in tumor progression. Biochemistry (Mosc). 2018;83(12):1469–76.CrossRef
10.
11.
Vu T, Datta PK. Regulation of EMT in colorectal cancer: a culprit in metastasis. Cancers (Basel). 2017;9(12):171.CrossRef
12.
Loh CY, et al. The E-Cadherin and N-Cadherin Switch in epithelial-to-mesenchymal transition: signaling, therapeutic implications, and challenges. Cells. 2019;8(10):1118.PubMedCentralCrossRef
13.
Leng Z, et al. Lgr5+CD44+EpCAM+ strictly defines cancer stem cells in human colorectal cancer. Cell Physiol Biochem. 2018;46(2):860–72.PubMedCrossRef
14.
15.
Javan B, Shahbazi M. Constructing a novel hypoxia-inducible bidirectional shRNA expression vector for simultaneous gene silencing in colorectal cancer gene therapy. Cancer Biother Radiopharm. 2018;33(3):118–23.PubMedCrossRef
16.
Sase T, et al. Runt-related transcription factor 2 in human colon carcinoma: a potent prognostic factor associated with estrogen receptor. Int J Cancer. 2012;131(10):2284–93.PubMedCrossRef
17.
18.
19.
Wang Q, et al. RUNX2 promotes hepatocellular carcinoma cell migration and invasion by upregulating MMP9 expression. Oncol Rep. 2016;36(5):2777–844.PubMedCrossRef
20.
21.
22.
Knutson TP, et al. Posttranslationally modified progesterone receptors direct ligand-specific expression of breast cancer stem cell-associated gene programs. J Hematol Oncol. 2017;10(1):89.PubMedPubMedCentralCrossRef
23.
Herreno AM, et al. Role of RUNX2 transcription factor in epithelial mesenchymal transition in non-small cell lung cancer lung cancer: Epigenetic control of the RUNX2 P1 promoter. Tumour Biol. 2019;41(5):1010428319851014.PubMedCrossRef
24.
Strobeck MW, et al. The BRG-1 subunit of the SWI/SNF complex regulates CD44 expression. J Biol Chem. 2001;276(12):9273–8.PubMedCrossRef
25.
Kuo KT, et al. Downregulation of BRG-1 repressed expression of CD44s in cervical neuroendocrine carcinoma and adenocarcinoma. Mod Pathol. 2006;19(12):1570–7.PubMedCrossRef
26.
Xi Q, et al. Genome-wide impact of the BRG1 SWI/SNF chromatin remodeler on the transforming growth factor beta transcriptional program. J Biol Chem. 2008;283(2):1146–55.PubMedCrossRef
27.
Sun J, et al. TRIM29 facilitates the epithelial-to-mesenchymal transition and the progression of colorectal cancer via the activation of the Wnt/beta-catenin signaling pathway. J Exp Clin Cancer Res. 2019;38(1):104.PubMedPubMedCentralCrossRef
28.
29.
Wasserman WW, Sandelin A. Applied bioinformatics for the identification of regulatory elements. Nat Rev Genet. 2004;5(4):276–87.PubMedCrossRef
30.
31.
Wu DM, et al. The PAX6-ZEB2 axis promotes metastasis and cisplatin resistance in non-small cell lung cancer through PI3K/AKT signaling. Cell Death Dis. 2019;10(5):349.PubMedPubMedCentralCrossRef
32.
Yamada D, et al. RUNX2 promotes malignant progression in glioma. Neurochem Res. 2018;43(11):2047–54.PubMedCrossRef
33.
Lu H, et al. RUNX2 plays an oncogenic role in esophageal carcinoma by activating the PI3K/AKT and ERK signaling pathways. Cell Physiol Biochem. 2018;49(1):217–25.PubMedCrossRef
34.
Jurkovicova D, et al. Evaluation of expression profiles of microRNAs and two target genes, FOXO3a and RUNX2, effectively supports diagnostics and therapy predictions in breast cancer. Neoplasma. 2016;63(6):941–51.PubMedCrossRef
35.
Yeung KT, Yang J. Epithelial-mesenchymal transition in tumor metastasis. Mol Oncol. 2017;11(1):28–39.PubMedCrossRef
36.
Cho SH, et al. CD44 enhances the epithelial-mesenchymal transition in association with colon cancer invasion. Int J Oncol. 2012;41(1):211–8.PubMed
37.
Muthuswami R, et al. BRG1 is a prognostic indicator and a potential therapeutic target for prostate cancer. J Cell Physiol. 2019;234(9):15194–205.PubMedCentralCrossRef
38.
39.
Lan J, et al. BRG1 promotes VEGF-A expression and angiogenesis in human colorectal cancer cells. Exp Cell Res. 2017;360(2):236–42.PubMedCrossRef
40.
Cerami E, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012;2(5):401–4.CrossRefPubMed
41.
Gorgen A, et al. The new era of transplant oncology: liver transplantation for nonresectable colorectal cancer liver metastases. Can J Gastroenterol Hepatol. 2018;2018:9531925.PubMedPubMedCentralCrossRef
42.
Villanueva F, et al. The cancer-related transcription factor RUNX2 modulates expression and secretion of the matricellular protein osteopontin in osteosarcoma cells to promote adhesion to endothelial pulmonary cells and lung metastasis. J Cell Physiol. 2019;234(8):13659–79.PubMedCrossRef
43.
44.
Qin L, et al. MicroRNA-455 regulates migration and invasion of human hepatocellular carcinoma by targeting RUNX2. Oncol Rep. 2016;36(6):3325–32.PubMedCrossRef
45.
Zhu X, Niu X, Ge C. Inhibition of LINC00994 represses malignant behaviors of pancreatic cancer cells: interacting with miR-765-3p/RUNX2 axis. Cancer Biol Ther. 2019;20(6):799–811.PubMedPubMedCentralCrossRef
46.
Wang ZQ, et al. Inhibition of RUNX2 transcriptional activity blocks the proliferation, migration and invasion of epithelial ovarian carcinoma cells. PLoS ONE. 2013;8(10):e74384.PubMedPubMedCentralCrossRef
47.
48.
Barutcu AR, et al. SMARCA4 regulates gene expression and higher-order chromatin structure in proliferating mammary epithelial cells. Genome Res. 2016;26(9):1188–201.PubMedPubMedCentralCrossRef
49.
50.
51.
Sethy R, et al. Regulation of ATM and ATR by SMARCAL1 and BRG1. Biochim Biophys Acta Gene Regul Mech. 2018;1861(12):1076–92.PubMedCrossRef
52.
53.
Banine F, et al. SWI/SNF chromatin-remodeling factors induce changes in DNA methylation to promote transcriptional activation. Cancer Res. 2005;65(9):3542–7.PubMedCrossRef
Metadata
Title
RUNX2 interacts with BRG1 to target CD44 for promoting invasion and migration of colorectal cancer cells
Authors
Xiaodong Yan
Dali Han
Zhiqiang Chen
Chao Han
Wei Dong
Li Han
Lei Zou
Jianbo Zhang
Yan Liu
Jie Chai
Publication date
01-12-2020
Publisher
BioMed Central
Published in
Cancer Cell International / Issue 1/2020
Electronic ISSN: 1475-2867
DOI
https://doi.org/10.1186/s12935-020-01544-w

Other articles of this Issue 1/2020

Cancer Cell International 1/2020 Go to the issue

Primary research

Targeted nanobody complex enhanced photodynamic therapy for lung cancer by overcoming tumor microenvironment

Primary research

Hsa_circ_0026416 promotes proliferation and migration in colorectal cancer via miR-346/NFIB axis

Primary research

Molecular targets of Yangyin Fuzheng Jiedu Prescription in the treatment of hepatocellular carcinoma based on network pharmacology analysis

Primary research

MCM3AP-AS1/miR-876-5p/WNT5A axis regulates the proliferation of prostate cancer cells

Primary research

Epstein–Barr virus infection and genome polymorphisms on gastric remnant carcinoma: a meta-analysis

Primary research

Circ0120816 acts as an oncogene of esophageal squamous cell carcinoma by inhibiting miR-1305 and releasing TXNRD1
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits